Clinical trials

2

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

Effect of Soya Bean on the Female Reproductive Hormones and Menopausal Symptoms

Menopause is one of the most emotionally, physically and Psychological miserable times in a woman's life.It occurs following cessation of menses resulting in the decline of endogenous estrogen. Phytoestrogens are natural plant derived compounds found in a wide variety of foods and soy bean is considered to be the richest source of plant estrogens. Current advances in management of menopause have relied on the use of hormone replacement therapy; however they are associated with adverse side effects if used over a long period of time. Currently, there is varying opinion regarding the physiological impact of soy bean consumption and results of studies are sparse and inconclusive. Hence, the need to determine the effect of soya bean consumption on the female reproductive hormones and relief of menopausal symptoms

Participants needed: 69
Trial details
Biological sex: FemaleType: InterventionalSponsor: Alex Ekwueme Federal University Teaching HospitalUpdated: Jul 31, 2026
Eligibility criteria

Women who gave consent [+2]

Women on hormone replacement therapy [+3]

Status: Not yet recruiting

The Efficacy of Carbitocin in Reduction of Blood Loss During Myomectomy

The uterine fibroids are the most common benign tumors found in the female reproductive system. Uterine fibroids commonly cause heavy menstrual periods. The prevalence of uterine fibroids is significantly affecting up to 70-80% of women by the age of 50, with an inconsistent impact on women of African origin. Carbitocin is a synthetic analogue of oxytocin which has a longer half-life than oxytocin. A Cochrane review and meta-analysis studies found that carbitocin reduced the use of additional uterotonics and transfusion. However, few of these studies was done during myomectomy.

Participants needed: 900
Trial details
Phase: Early Phase 1Biological sex: FemaleType: InterventionalSponsor: Alex Ekwueme Federal University Teaching HospitalUpdated: Jul 23, 2026
Eligibility criteria

All consented women booked for myomectomy. [+2]

Declined consent [+10]